Nurix Therapeutics (NRIX)

Nurix Therapeutics (NRIX) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

Sanofi setback weighs as investors await trial data

Nurix slipped 0.9% today while the S&P 500 and Nasdaq 100 rose, extending a steep monthly decline. Sanofi’s decision to end a partnered drug program remains a recent concern; investors are also looking to upcoming cancer-trial data and Nurix’s next report.

Published 2026-11-19 15:01:41 UTC.